Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.